Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination with enfortumab vedotin for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) who have not received prior systemic therapy for this condition. This decision […]
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. This potent combination significantly improved overall survival (OS) and progression-free survival (PFS) for patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Highlighted Findings from the EV-302 Study […]
Astellas Pharma has signed an agreement to acquire a 15% stake in US-based biotech company Taysha GeneTherapies through an investment of $50 million. As part of the transaction, the Japanese pharmaceutical company will get an exclusive option to license Taysha GeneTherapies’ TSHA-102 and TSHA-120, two clinical-stage, single-gene therapies for rare genetic diseases. TSHA-102 is a […]
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) for the treatment of advanced urothelial cancer, the most common form of bladder cancer. Padcev, which has been co-developed by the two pharma companies, is a Nectin-4-directed antibody and microtubule […]
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]